Day 1 |
Binding antibody assay positive, n (%) | 0 | 0 | 0 |
Neutralising antibody assay positive, n (%) | 0 | 0 | 0 |
Day 16 |
Binding antibody assay positive, n (%) | 12 (17.9) | 12 (17.4) | 23 (34.8) |
Neutralising antibody assay positive, n (%) | 0 | 0 | 0 |
Day 29 |
Binding antibody assay positive, n (%) | 21 (31.8) | 27 (41.5) | 27 (41.5) |
Neutralising antibody assay positive, n (%) | 0 | 0 | 2 (3) |
End of study (day 63) |
Binding antibody assay positive, n (%) | 29 (43.3) | 34 (50.0) | 34 (50.7) |
Neutralising antibody assay positive, n (%) | 12 (17.9) | 15 (21.7) | 13 (19.4) |
Anytime |
Binding antibody assay positive, n (%) | 36 (53.7) | 38 (55.1) | 45 (67.2) |
Neutralising antibody assay positive, n (%) | 12 (17.9) | 15 (21.7) | 14 (20.9) |